Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
NCT05757713Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2023
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Started Jul 2023; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05757713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757713.